source
- Melanoma patient shares hope after receiving Merck-Moderna mRNA cancer vaccine in trialA schoolteacher diagnosed with melanoma in 2019 participated in a late‑stage trial testing an mRNA cancer vaccine developed by Merck and Moderna. The trial added the vaccine to standard immunothera…
- OrbiMed secures $3 billion for new life science funds, with over $1 billion earmarked for AsiaOrbiMed, a leading global investor in life science companies, announced the closing of two new funds that together total about $3 billion. The capital will be deployed across a range of private equ…